176 related articles for article (PubMed ID: 36394373)
1. Antineoplastic chemotherapy and immunosuppression in liver transplant recipients: Squaring the circle?
Coupier A; Gallien Y; Boillot O; Walter T; Guillaud O; Vallin M; Thimonier E; Erard D; Dumortier J
Clin Transplant; 2023 Jan; 37(1):e14841. PubMed ID: 36394373
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
4. Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.
Ivulich S; Paul E; Kirkpatrick C; Dooley M; Snell G
Transpl Int; 2023; 36():10704. PubMed ID: 36744051
[TBL] [Abstract][Full Text] [Related]
5. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of everolimus initiation from the first month after liver transplantation: A systematic review and meta-analysis.
Cholongitas E; Burra P; Vourli G; Papatheodoridis GV
Clin Transplant; 2023 May; 37(5):e14957. PubMed ID: 36880482
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
8. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital.
San Miguel C; Fundora Y; Triguero J; Muffak K; Villegas T; Becerra A; Garrote D; Ferrón JA
Transplant Proc; 2015 Oct; 47(8):2371-3. PubMed ID: 26518930
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
12. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
13. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.
Vivarelli M; Risaliti A
World J Gastroenterol; 2011 Nov; 17(43):4741-6. PubMed ID: 22147974
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression.
Liu YY; Li CP; Huai MS; Fu XM; Cui Z; Fan LL; Zhang S; Liu Y; Ma J; Li G; Shen ZY
PLoS One; 2015; 10(3):e0120939. PubMed ID: 25816221
[TBL] [Abstract][Full Text] [Related]
15. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation.
Cholongitas E; Antoniadis N; Goulis I; Theocharidou E; Ιmvrios G; Giouleme O; Filis D; Mouloudi E; Akriviadis E; Fouzas I
Transplant Proc; 2019 Mar; 51(2):450-453. PubMed ID: 30879564
[TBL] [Abstract][Full Text] [Related]
16. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
17. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma.
Rodríguez-Perálvarez M; Tsochatzis E; Naveas MC; Pieri G; García-Caparrós C; O'Beirne J; Poyato-González A; Ferrín-Sánchez G; Montero-Álvarez JL; Patch D; Thorburn D; Briceño J; De la Mata M; Burroughs AK
J Hepatol; 2013 Dec; 59(6):1193-9. PubMed ID: 23867318
[TBL] [Abstract][Full Text] [Related]
18. Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes.
Bittermann T; Lewis JD; Goldberg DS
Transplantation; 2022 Nov; 106(11):2182-2192. PubMed ID: 35706103
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006.
Na R; Laaksonen MA; Grulich AE; Webster AC; Meagher NS; McCaughan GW; Keogh AM; Vajdic CM
Clin Transplant; 2015 Nov; 29(11):978-90. PubMed ID: 26278925
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity.
Bilbao I; Dopazo C; Castells L; Lazaro J; Caralt M; Sapisochin G; Charco R
Transplant Proc; 2014 Nov; 46(9):3104-7. PubMed ID: 25420835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
